1. Long-term standard sentinel node biopsy after neoadjuvant treatment in breast cancer: a single institution ten-year follow-up
- Author
-
Kahler-Ribeiro-Fontana, S, Pagan, E, Magnoni, F, Vicini, E, Morigi, C, Corso, G, Intra, M, Canegallo, F, Ratini, S, Leonardi, M, La Rocca, E, Bagnardi, V, Montagna, E, Colleoni, M, Viale, G, Bottiglieri, L, Grana, C, Biasuz, J, Veronesi, P, Galimberti, V, Kahler-Ribeiro-Fontana, Sabrina, Pagan, Eleonora, Magnoni, Francesca, Vicini, Elisa, Morigi, Consuelo, Corso, Giovanni, Intra, Mattia, Canegallo, Fiorella, Ratini, Silvia, Leonardi, Maria Cristina, La Rocca, Eliana, Bagnardi, Vincenzo, Montagna, Emilia, Colleoni, Marco, Viale, Giuseppe, Bottiglieri, Luca, Grana, Chiara Maria, Biasuz, Jorge Villanova, Veronesi, Paolo, Galimberti, Viviana, Kahler-Ribeiro-Fontana, S, Pagan, E, Magnoni, F, Vicini, E, Morigi, C, Corso, G, Intra, M, Canegallo, F, Ratini, S, Leonardi, M, La Rocca, E, Bagnardi, V, Montagna, E, Colleoni, M, Viale, G, Bottiglieri, L, Grana, C, Biasuz, J, Veronesi, P, Galimberti, V, Kahler-Ribeiro-Fontana, Sabrina, Pagan, Eleonora, Magnoni, Francesca, Vicini, Elisa, Morigi, Consuelo, Corso, Giovanni, Intra, Mattia, Canegallo, Fiorella, Ratini, Silvia, Leonardi, Maria Cristina, La Rocca, Eliana, Bagnardi, Vincenzo, Montagna, Emilia, Colleoni, Marco, Viale, Giuseppe, Bottiglieri, Luca, Grana, Chiara Maria, Biasuz, Jorge Villanova, Veronesi, Paolo, and Galimberti, Viviana
- Abstract
Introduction: In patients with positive lymph nodes (cN+) prior to neoadjuvant treatment (NAT), which convert to a clinically negative axilla (cN0) after treatment, the use of sentinel node biopsy (SNB) is still debatable, since the false-negative rate (FNR) is significantly high (12.6–14.2%). The objective of this retrospective mono-institutional study, with a long follow-up, aimed to evaluate the outcome in patients undergoing NAT who remained or converted to cN0 and received SNB independent of target axillary dissection (TAD) or the removal of at least 3 sentinel nodes (SNs). Methods: This study analyzed 688 consecutive cT1-3, cN0/1/2 patients, operated at the European Institute of Oncology, Milan, from 2000 to 2015 who became or remained cN0 after NAT and underwent SNB with a least one SN found. Axillary dissection (AD) was not performed if the SN was negative. Nodal radiotherapy (RT) was not mandatory. Results: Axillary failure occurred in 1.8% of the initially cN1/2 patients and in 1.5% of the initially cN0 patients. After a median follow-up of 9.2 years (IQR 5.3–12.3), the 5- and 10-year overall survival (OS) were 91.3% (95% CI, 88.8–93.2) and 81.0% (95% CI, 77.2–84.2) in the whole cohort, 92.0% (95% CI, 89.0–94.2) and 81.5% (95% CI, 76.9–85.2) in those initially cN0, 89.8% (95% CI, 85.0–93.2) and 80.1% (95% CI, 72.8–85.7) in those initially cN1/2. Conclusion: The 10-year follow-up confirmed our preliminary data that the use of standard SNB is acceptable in cN1/2 patients who become cN0 after NAT and will not translate into a worse outcome.
- Published
- 2021